CA 50 is a new tumor marker based on a monoclonal anti-carcinoid tumor, 2 cystadenocarcinomas, 2 anaplastic carcibody (MAb) against a human colorectal carcinoma cell line.The nomas, 15 poorly differentiated and 39 well-to moderately-CA 50 antigen is similar, but not identical, to the tumor different
✦ LIBER ✦
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer
✍ Scribed by Haglund, C; Roberts, P J; Kuusela, P; Scheinin, T M; Mäkelä, O; Jalanko, H
- Book ID
- 109835794
- Publisher
- Nature Publishing Group
- Year
- 1986
- Tongue
- English
- Weight
- 678 KB
- Volume
- 53
- Category
- Article
- ISSN
- 0007-0920
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Serum ca 50 as a tumor marker in pancrea
✍
Caj Haglund; Pentti Kuusela; Hannu Jalanko; Peter J. Roberts
📂
Article
📅
1987
🏛
John Wiley and Sons
🌐
French
⚖ 459 KB
Tumour marker antigen CA125 in pancreati
✍
Haglund, C
📂
Article
📅
1986
🏛
Nature Publishing Group
🌐
English
⚖ 565 KB
Serum CA 19-9 as a Biomarker for Pancrea
✍
Umashankar K. Ballehaninna; Ronald S. Chamberlain
📂
Article
📅
2011
🏛
Springer-Verlag
🌐
English
⚖ 218 KB
Clinical evaluation of a new serum tumou
✍
Pasanen, PA; Eskelinen, M; Partanen, K; Pikkarainen, P; Penttilä, I; Alhava, E
📂
Article
📅
1992
🏛
Nature Publishing Group
🌐
English
⚖ 725 KB
Prognostic significance of serum CA19-9
✍
Fujimoto, Koji ;Koizumi, Shunzou ;Nishimura, Satoru ;Sakai, Satoaki ;Nakamura, Y
📂
Article
📅
1996
🏛
Springer
🌐
English
⚖ 512 KB
CA 19-9 as a prognostic index after rese
✍
Cosimo Sperti; Claudio Pasquali; Sandra Catalini; Francesco Cappellazzo; Bruno B
📂
Article
📅
1993
🏛
John Wiley and Sons
🌐
English
⚖ 485 KB
Serial serum CA 19-9 assays were performed in 30 consecutive patients who underwent resection for pancreatic cancer. Patients with preoperative CA 19-9 levels < 200 U/ml had significantly better prognosis than those with CA 19-9 > 200 Ulml ( P < 0.001). Serum tumor marker normalized in 14 patients a